TY - JOUR
T1 - Melanoma associated with long-term voriconazole therapy
T2 - A new manifestation of chronic photosensitivity
AU - Miller, Daniel D.
AU - Cowen, Edward W.
AU - Nguyen, Josephine C.
AU - McCalmont, Timothy H.
AU - Fox, Lindy P.
PY - 2010/3
Y1 - 2010/3
N2 - Background: Voriconazole is a triazole antifungal agent approved by the US Food and Drug Administration for serious fungal infections, including with Aspergillus, Fusarium, Pseudallescheria, and Scedosporium species. In initial clinical trials, approximately 2% of patients developed cutaneous reactions, including photosensitivity, cheilitis, and xerosis. Subsequent reports have implicated voriconazole as a cause of severe photosensitivity and accelerated photoaging, pseudoporphyria cutanea tarda, and aggressive squamous cell carcinoma. Observation: We report 5 melanoma in situ lesions in the setting of extreme photosensitivity associated with long-term voriconazole therapy. Conclusions: We recommend surveillance for skin cancer formation in all patients who require long-term voriconazole treatment, particularly those who manifest signs or symptoms of photosensitivity or chronic photodamage. Further study of the mechanism underlying voriconazole photosensitivity and oncogenesis is warranted.
AB - Background: Voriconazole is a triazole antifungal agent approved by the US Food and Drug Administration for serious fungal infections, including with Aspergillus, Fusarium, Pseudallescheria, and Scedosporium species. In initial clinical trials, approximately 2% of patients developed cutaneous reactions, including photosensitivity, cheilitis, and xerosis. Subsequent reports have implicated voriconazole as a cause of severe photosensitivity and accelerated photoaging, pseudoporphyria cutanea tarda, and aggressive squamous cell carcinoma. Observation: We report 5 melanoma in situ lesions in the setting of extreme photosensitivity associated with long-term voriconazole therapy. Conclusions: We recommend surveillance for skin cancer formation in all patients who require long-term voriconazole treatment, particularly those who manifest signs or symptoms of photosensitivity or chronic photodamage. Further study of the mechanism underlying voriconazole photosensitivity and oncogenesis is warranted.
UR - http://www.scopus.com/inward/record.url?scp=77949373240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77949373240&partnerID=8YFLogxK
U2 - 10.1001/archdermatol.2009.362
DO - 10.1001/archdermatol.2009.362
M3 - Article
C2 - 20083676
AN - SCOPUS:77949373240
SN - 0003-987X
VL - 146
SP - 300
EP - 304
JO - Archives of Dermatology
JF - Archives of Dermatology
IS - 3
ER -